Latest News
Keep up to date with all our latest investments, service offerings and news items.
Click here to view our latest media kit
-
June 18, 2020 -
May 14, 2020 Almac Discovery Enters Into Licensing Agreement for the Development & Commercialisation of ALM301
-
April 29, 2020 Almac Discovery to Collaborate with MSD on selected DUB therapeutic targets
-
March 5, 2020 Debiopharm Advances its Potent Wee1 Inhibitor into Clinical Phase
-
October 1, 2019 Almac Group Appoints Dr Alan Lamont as VP BD & Licensing
-
March 20, 2019 Almac Discovery and Elasmogen to Share Anti-ROR-1 VNAR Data at American Association of Cancer Annual Meeting
-
March 18, 2019 Almac Discovery Showcases its Deubiquitinase Drug Discovery Expertise at the American Association of Cancer Research Annual Meeting in Atlanta
-
August 6, 2018 VNAR Based Oncology Platform in development
-
July 5, 2018 Dr. Xavier Jacq Appointed Vice President, Biology
-
April 23, 2018 Latest developments in DUB inhibitors shared at Proteasome & Autophagy Congress
-
April 10, 2018 Almac Discovery to Present at AACR 2018
-
January 29, 2018 Research Highlighted in Nature Chemical Biology
-
December 4, 2017 USP7 inhibitors from UbiPlexTM Platform published
-
September 4, 2017 ALM201 Poster Presentation at 2017 ESMO Congress
-
July 3, 2017 ALM201 – Orphan Drug Designation Granted in Ovarian Cancer
-
June 20, 2017 Agreement with Debiopharm to Develop Novel Wee-1 Inhibitor
-
May 8, 2017 Wee-1 kinase patent approval granted
-
February 14, 2017 Therapy-resistant cancer tumours targeted with RCSI
-
May 30, 2016 Diseases of the eye explored with McClay Foundation and UU
-
October 5, 2015 European Patent Protection for ALM201 Secured
-
July 10, 2015 Ubiquitin Specific Protease Collaboration with Genentech
-
September 4, 2013 £13m Investment Cancer Research Initiatives with QUB
-
April 27, 2009 Minister Praises Craigavon Life Sciences Firm’s Commitment to R&D
-
June 10, 2008 Almac Group Launches Oncology Discovery Arm